Thus, it is understandable that the absence of IL-33 in IL-33−/− mice at the early stage of the patent infection might have left ILC2 inactivated, leading to impaired type 2 immunity [59], as seen in the present study (Fig. 2a, b). This evidence concerns the gene IL33 and infection.